Alcobra Ltd. (NASDAQ:ADHD) – Analysts at Oppenheimer Holdings cut their FY2016 earnings per share (EPS) estimates for Alcobra in a research note issued on Tuesday. Oppenheimer Holdings analyst J. Olson now forecasts that the firm will post earnings of ($1.04) per share for the year, down from their prior forecast of ($0.98). Oppenheimer Holdings currently has a “Market Perform” rating on the stock. Oppenheimer Holdings also issued estimates for Alcobra’s Q4 2016 earnings at ($0.36) EPS.

Alcobra (NASDAQ:ADHD) last posted its quarterly earnings data on Tuesday, November 15th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.26) by $0.02. The company had revenue of $7.90 million for the quarter, compared to analysts’ expectations of $4.30 million.

Earnings History and Estimates for Alcobra (NASDAQ:ADHD)

ADHD has been the subject of several other research reports. Roth Capital set a $8.00 target price on shares of Alcobra and gave the stock a “buy” rating in a research note on Saturday, October 1st. Zacks Investment Research lowered shares of Alcobra from a “buy” rating to a “hold” rating in a research note on Friday. WBB Securities raised shares of Alcobra from a “sell” rating to a “hold” rating and lowered their target price for the stock from $4.00 to $1.90 in a research note on Wednesday, November 2nd. Piper Jaffray Cos. lowered shares of Alcobra from an “overweight” rating to a “neutral” rating and lowered their target price for the stock from $10.00 to $3.00 in a research note on Thursday, September 29th. Finally, Cantor Fitzgerald lowered shares of Alcobra from a “buy” rating to a “hold” rating and set a $2.00 target price for the company. in a research note on Thursday, September 29th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $5.14.

Alcobra (NASDAQ:ADHD) opened at 2.03 on Friday. The company’s 50 day moving average is $2.21 and its 200 day moving average is $4.01. The company’s market cap is $55.95 million. Alcobra has a 1-year low of $1.77 and a 1-year high of $6.80.

A number of hedge funds and other institutional investors have recently modified their holdings of ADHD. Baker BROS. Advisors LP purchased a new position in shares of Alcobra during the third quarter worth about $5,771,000. Knoll Capital Management LP purchased a new position in shares of Alcobra during the third quarter worth about $2,799,000. VHCP Management II LLC increased its position in shares of Alcobra by 28.7% in the second quarter. VHCP Management II LLC now owns 1,454,402 shares of the company’s stock worth $6,530,000 after buying an additional 323,902 shares in the last quarter. VHCP Management LLC increased its position in shares of Alcobra by 28.7% in the second quarter. VHCP Management LLC now owns 623,313 shares of the company’s stock worth $2,799,000 after buying an additional 138,813 shares in the last quarter. Finally, Jefferies Group LLC purchased a new position in shares of Alcobra during the second quarter worth about $533,000. Institutional investors own 73.72% of the company’s stock.

About Alcobra

Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.

5 Day Chart for NASDAQ:ADHD

Receive News & Stock Ratings for Alcobra Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd. and related stocks with our FREE daily email newsletter.